Journal of Antimicrobial Chemotherapy

Article	Citations
ResFinder 4.0 for predictions of phenotypes from genotypes	1469
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression	358
Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder	261
COVID-19 and the potential long-term impact on antimicrobial resistance	227
Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey	168
Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9	157
Systematic review of mutations associated with resistance to the new and repurposedMycobacterium tuberculosisdrugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid	114
The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community	105
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study	102
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis	96
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19	87
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	85
Implications of antibiotics use during the COVID-19 pandemic: present and future	82
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey	81
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia	77
Favipiravir, an antiviral for COVID-19?	77
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	76
EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories	75
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	71
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London	71
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola viru	67
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomize	64
Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review	58
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	56
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries	55

Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital	53
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19	52
Lopinavir pharmacokinetics in COVID-19 patients	50
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study	50
Linezolid resistance in Enterococcus faecium and Enterococcus faecalis from hospitalized patients in Ireland: high prevalence of the MDR genes optrA and poxtA in isolates with diverse genetic backgrou	47
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages	43
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection	43
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia	43
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect	43
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii	42
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients	42
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections	42
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	41
Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it	41
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge	40
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU	37
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved	37
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model	36
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections	35
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes	35
Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics	35
Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfectio	34
Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans	33
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019	33
Relationship of vancomycin trough levels with acute kidney injury risk: an exposure–toxicity meta-analysis	33
Linezolid-resistant (Tn6246::fexB-poxtA) Enterococcus faecium strains colonizing humans and bovines on different continents: similarity without epidemiological link	33
Molecular and functional analysis of the novel cfr(D) linezolid resistance gene identified in Enterococcus faecium	33
Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile	33
Characterization of a porcine Proteus cibarius strain co-harbouring tet(X6) and cfr	33
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid	32
In vitrosusceptibility ofMycobacterium abscessuscomplex and feasibility of standardizing treatment regimens	31
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018	31
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates	31
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017	31
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases	31
Global clonal spread of mcr-3-carrying MDR ST34 Salmonella enterica serotype Typhimurium and monophasic 1,4,[5],12:i:− variants from clinical isolates	31
Impact of an antimicrobial stewardship programme on reducing broad-spectrum antibiotic use and its effect on carbapenem-resistantAcinetobacter baumannii(CRAb) in hospitals in Jordan	30
Clofazimine pharmacokinetics in patients with TB: dosing implications	29
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China	29
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa	29
Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis	29
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)	29
AMR-Intervene: a social–ecological framework to capture the diversity of actions to tackle antimicrobial resistance from a One Health perspective	28
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?	28
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients	28
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?	28
Genomic epidemiology of Neisseria gonorrhoeae elucidating the gonococcal antimicrobial resistance and lineages/sublineages across Brazil, 2015–16	28
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis	28
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia	28
Dissemination of the blaCTX-M-15 gene among Enterobacteriaceae via outer membrane vesicles	28

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies	28
Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 2019	27
Do high MICs predict the outcome in invasive fusariosis?	27
Transferable Acinetobacter baumannii plasmid pDETAB2 encodes OXA-58 and NDM-1 and represents a new class of antibiotic resistance plasmids	27
IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bactera	27
Sustained transmission of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China	27
ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi	26
Indications for the use of highest priority critically important antimicrobials in the veterinary sector	26
Evolution of β-lactamase-mediated cefiderocol resistance	26
High percentage of the ceftriaxone-resistantNeisseria gonorrhoeaeFC428 clone among isolates from a single hospital in Hangzhou, China	26
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19	26
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre	26
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli	26
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection	25
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria	25
Studies on the role of IS1216E in the formation and dissemination of poxtA-carrying plasmids in an Enterococcus faecium clade A1 isolate	25
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial	25
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial	25
Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections	25
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis	25
Antibiotics and healthcare facility-associatedClostridioides difficileinfection: systematic review and meta-analysis 2020 update	25
Molecular epidemiology of carbapenemase-producingEscherichia colifrom duck farms in south-east coastal China	25
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa	24
Prevalence of third-generation cephalosporin-resistant Enterobacterales colonization on hospital admission and ESBL genotype-specific risk factors: a cross-sectional study in six German university hos	24
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications	24
Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of Acinetobacter baumannii	24
Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interv	24
Detection ofmcr-9-harbouring ESBL-producingSalmonellaNewport isolated from an outbreak in a large-animal teaching hospital in the USA	24
On the island of Zanzibar people in the community are frequently colonized with the same MDR Enterobacterales found in poultry and retailed chicken meat	24
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales	23
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)	23
A novel in silico antimicrobial peptide DP7 combats MDR Pseudomonas aeruginosa and related biofilm infections	23
Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology	23
Antimicrobial susceptibility of Corynebacterium diphtheriae and Corynebacterium ulcerans in Germany 2011–17	23
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial	23
Ganciclovir therapeutic drug monitoring in transplant recipients	23
Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection	23
Prevalence and genomic analysis of ESBL-producingEscherichia coliin retail raw meats in Singapore	23
Integration of the blaNDM-1 carbapenemase gene into a novel SXT/R391 integrative and conjugative element in Proteus vulgaris	23
Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background	23
In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies	23
Extensive antimicrobial resistance mobilization via multicopy plasmid encapsidation mediated by temperate phages	23
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review	23
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK	23
Emergence of a multidrug resistance efflux pump with carbapenem resistance gene blaVIM-2 in a Pseudomonas putida megaplasmid of migratory bird origin	23
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa	22
Characterization of Klebsiella pneumoniae complex isolates from pigs and humans in farms in Thailand: population genomic structure, antibiotic resistance and virulence genes	22
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18	22
Characterization of AmpC-hyperproducing Escherichia coli from humans and dairy farms collected in parallel in the same geographical region	22
In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies	22
Class D β-lactamases	22
Emergence of OXA-232-producing hypervirulent Klebsiella pneumoniae ST23 causing neonatal sepsis	22
In vitroactivity of rifabutin against 293 contemporary carbapenem-resistantAcinetobacter baumanniiclinical isolates and characterization of rifabutin mode of action and resistance mechan	22
Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic	22
In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria	21
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial	21
Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study	21
Delamanid or pretomanid? A Solomonic judgement!	21
A review of remdesivir for COVID-19 in pregnancy and lactation	21
A novel plasmid-borne tet(X6) variant co-existing with blaNDM-1 and blaOXA-58 in a chicken Acinetobacter baumannii isolate	21
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring	21
Preliminary view of the global distribution and spread of the tet(X) family of tigecycline resistance genes	21
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study	21
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–	21
Novel IncFII plasmid harbouring blaNDM-4 in a carbapenem-resistant Escherichia coli of pig origin, Italy	21
Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening	21
In vitroactivity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli fro	20
Characterization and outcome of invasive infections due toPaecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports	20
Inherent colistin resistance in genogroups of the Enterobacter cloacae complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme	20
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing	20
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study	20
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis	20
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China	20
Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin	19
Treating COVID-19: are we missing out the window of opportunity?	19
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2	19
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	19
Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach	19
Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres	19
Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review	19

The effect of N-acetylcysteine in a combined antibiofilm treatment against antibiotic-resistant Staphylococcus aureus	19
Establishing essential metrics for antifungal stewardship in hospitals: the results of an international Delphi survey	19
Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and	19
Revealing antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling	19
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis	19
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting	19
Identification of thresholds in relationships between specific antibiotic use and carbapenem-resistant Acinetobacter baumannii (CRAb) incidence rates in hospitalized patients in Jordan	19
Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey	19
Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae	19
Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and	19
One Health compartmental analysis of ESBL-producing Escherichia coli on Reunion Island reveals partitioning between humans and livestock	19
Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019	19
Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020–21	19
Multiplex real-time PCR assays for the prediction of cephalosporin, ciprofloxacin and azithromycin antimicrobial susceptibility of positive Neisseria gonorrhoeae nucleic acid amplification test	19
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates	19
Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients	19
Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children	19
Neisseria gonorrhoeaeSequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antim	18
COVID-19, antibiotics and One Health: a UK environmental risk assessment	18
Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro	18
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments	18
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	18
Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations	18
Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China	18
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study	18
Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases	18
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?	18
De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shoc	18
Spread of ESC-, carbapenem- and colistin-resistant Escherichia coli clones and plasmids within and between food workers in Lebanon	18
Characterization of novel ISAba1-bounded tet(X15)-bearing composite transposon Tn6866 in Acinetobacter variabilis	18
IS26cannot move alone	17
Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study	17
Impact of duration of antibiotic therapy in central venous catheter-related bloodstream infection due to Gram-negative bacilli	17
Role of new antibiotics for KPC-producingKlebsiella pneumoniae	17
Invasive infections withPurpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature	17
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3	17
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients	17
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure	17
Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory	17
EUCAST rapid antimicrobial susceptibility testing (RAST): analytical performance and impact on patient management	17
Repositioning rafoxanide to treat Gram-negative bacilli infections	17
Two high-risk clones of carbapenemase-producing Klebsiella pneumoniae that cause infections in pets and are present in the environment of a veterinary referral hospital	16
Characterization of carbapenemase-producingSerratia marcescensand whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016–18)	16
Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and charact	16
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation	16
Dalbavancin for the management of osteomyelitis: a major step forward?	16
Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis	16
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control	16
Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials	16
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones	16
Antifungal activity of nikkomycin Z against Candida auris	16
Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis	16
Molecular genetic analysis of an XDR Pseudomonas aeruginosa ST664 clone carrying multiple conjugal plasmids	16
Detection in livestock of the human pandemic Escherichia coli ST131 fimH30(R) clone carrying blaCTX-M-27	16
Consumption of quinolones in the community, European Union/European Economic Area, 1997–2017	16
Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time	16
Microevolution of acquired colistin resistance in Enterobacteriaceae from ICU patients receiving selective decontamination of the digestive tract	16
Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants	16
Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain	16
Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark	16
Mechanisms of antibiotic resistance of Clostridioides difficile	16
Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world	16
Comparative genomics of ESBL-producingEscherichia coli(ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-inte	16
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers	16
Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing Klebsiella pneumoniae originating from companion animals and humans	16
Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection	16
AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates	16
Emergence of a Neisseria gonorrhoeae clone with reduced cephalosporin susceptibility between 2014 and 2019 in Amsterdam, The Netherlands, revealed by genomic population analysis	16
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19	16
Occurrence of a plasmid co-carrying cfr(D) and poxtA2 linezolid resistance genes in Enterococcus faecalis and Enterococcus casseliflavus from porcine manure, Italy	16
Carbapenemase-producing Enterobacteriaceae in transplant patients	16
High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort s	16
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods	15
Point prevalence survey of antibiotic use in hospitals in Latin American countries	15
Detecting carbapenemase-producing Enterobacterales (CPE): an evaluation of an enhanced CPE infection control and screening programme in acute care	15
Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study	15
Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015–19)	15
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis	15
Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria	15
When to change treatment of acute invasive aspergillosis: an expert viewpoint	15
Emergence of CTX-M-27-producing Escherichia coli of ST131 and clade C1-M27 in an impacted ecosystem with international maritime traffic in South America	15
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation	15
A novel colistin adjuvant identified by virtual screening for ArnT inhibitors	15
In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae	15
Azithromycin in patients with COVID-19: a systematic review and meta-analysis	15
Emergence of livestock-associated MRSA ST398 from bulk tank milk, China	15
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics	15
Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli	15
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital	15
Emergence and genomic characterization of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in Chengdu, China	15
Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveil	14
An outbreak of multiply antibiotic-resistant ST49:ST128:KL11:OCL8Acinetobacter baumanniiisolates at a Sydney hospital	14
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales	14
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections	14
Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK	14